Big data: the opportunity to think outside the discipline

Affiliations

Comment

Marta E Alarcón-Riquelme. Nat Rev Rheumatol. 2019 Nov.

. 2019 Nov;15(11):639-640.

doi: 10.1038/s41584-019-0292-9.

¹ GENYO. Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain. marta.alarcon@genyo.es.

No abstract available

Comment on

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.
Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake TRDJ. Gossec L, et al. Ann Rheum Dis. 2020 Jan;79(1):69-76. doi: 10.1136/annrheumdis-2019-215694. Epub 2019 Jun 22. Ann Rheum Dis. 2020. PMID: 31229952

1. Gossec, L. et al. EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-215694 (2019). - DOI - PubMed
1. Tedeschi, S. K. et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res. 4, 571–581 (2016).
1. ELIXIR. ELIXIR Data Platform. Elixir-europe.org https://www.elixir-europe.org/platforms/data (2017).
1. Kinkorová, J. & Topolcˇan, O. Biobanks in Horizon 2020: sustainability and attractive perspectives. EPMA J. 9, 345–353 (2018). - DOI
1. Barturen, G. et al. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75–93 (2018). - DOI